Investigating the role of AR extrachromosomal DNA (ECDNA) in bipolar androgen therapy for advanced prostate cancer
Active Project Grant Awarded Last action
- Award ID
- F30CA314114
- Recipient
-
Regents Of The University Of Minnesota UEI KABJZBBJ4B54
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $89,638
Award facts
- Assistance listing
- 93.398 Cancer Research Manpower
- Completion date 0% complete
- Originally
- Place of performance
- Minneapolis, MN 55455, USA
Award details come from USAspending.gov.
Description
- Abstract
- Prostate cancer is one of the most common malignancies and a leading cause of cancer-related deaths in american men. In advanced prostate cancer, androgen deprivation therapy (ADT) is the standard of care. While most patients initially respond to ADT, they will eventually develop castration resistant prostate cancer (CRPC). CRPC is a lethal and aggressive disease stage with limited treatment options. A novel therapeutic strategy for CRPC is bipolar androgen therapy (BAT). Clinical trials have demonstrated both safety and efficacy, as well as improvements in quality of life with the use of BAT. However, the patient populations best suited for BAT and the mechanism of anti-tumor activity in patients who respond to BAT remain undefined. CRPC is associated with amplification and overexpression of the androgen receptor (AR). One mechanism of AR amplification is extrachromosomal DNA (ECDNA). Ecdnas are MB-sized circular structures located in the nucleus that allow for increased rates of transcription and replication, with new studies estimating that 1/3 of CRPC tumors likely contain AR ECDNA. Preliminary data in this project indicate that CRPC patient-derived xenografts (PDXS) classified as positive for AR ECDNA are sensitive to BAT. Based on this finding, my research training will explore AR ECDNA as a therapeutic vulnerability and biomarker to identify patient populations that should be considered for BAT. The central hypothesis is that AR ECDNA levels are dynamic during ADT and BAT, and that BAT inhibits AR ECDNA-positive CRPC by inducing R-loops, transcription-replication collisions, and DNA damage on ECDNA. Aim 1 will utilize computational tools to investigate the composition of ECDNA and how treatment affects quantity of AR ECDNA structures. Aim 2 will investigate the mechanism of BAT in ECDNA- positive tumors, assessing the vulnerability of these structures to excess DNA damage during treatment. This project is specifically designed to provide rigorous training in key areas for my development as an independent physician-scientist. Aim 1 will provide hands-on training in computational biology and who genome sequencing data. Aim 2 will build my expertise in advanced molecular biology techniques to probe mechanisms by which BAT enhances transcription and DNA damage. Completing this project will advance our understanding of the role of AR ECDNA in BAT sensitivity and biological mechanisms of action and provide me with the conceptual knowledge and technical skills necessary to lead a research project focused on translating mechanistic discoveries into novel cancer therapies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $44,819 | |
| Amendment | $44,819 | |
| Original award | $0 |
Quick answers
Who received award F30CA314114?
F30CA314114 was awarded to Regents Of The University Of Minnesota by National Cancer Institute (National Institutes of Health) on December 1, 2026.
How much is award F30CA314114 worth?
$89,638 has been obligated on F30CA314114.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award